Historically, it has been common practice to maintain hypocapnia (arterial carbon dioxide pressure (PaCO~2~) \< 35 mmHg) during general anesthesia.[@CR1],[@CR2] Intraoperative end-tidal carbon dioxide (ETCO~2~) values around 30 mmHg were frequently targeted, as hypercapnia (PaCO~2~ \> 45 mmHg) was considered to contribute to intraoperative tachycardia and hypertension, thereby increasing the oxygen demand of the myocardium.[@CR1],[@CR3] In contrast, hypocapnia reduced the need for muscle relaxants and additional anesthetics to prevent spontaneous ventilation. Nevertheless, there is no good evidence to support the benefit of hypocapnia, and some studies suggest benefits for higher ETCO~2~ levels.[@CR1],[@CR4],[@CR5] First, it is easier to implement low tidal volume ventilation.[@CR6],[@CR7] Second, hypercapnia increases the cardiac output, resulting in an increase in tissue oxygenation, which in turn may prevent surgical site infections.[@CR1],[@CR8]-[@CR10] Third, studies using different lung injury models have shown that hypercapnia has protective, immune-modulating properties that decrease the inflammatory response.[@CR11]-[@CR13] Fourth, hypercapnia may increase lung parenchymal compliance[@CR13]-[@CR15] and can improve ventilation-perfusion matching in the lungs.[@CR1],[@CR12],[@CR16] Finally, normocapnia positively influences the neurologic outcome because of vasoactive properties of PaCO~2~, which is especially pronounced in already injured brains.[@CR17]

Unfortunately, many studies focus on the critical care population, leaving surgical patients underrepresented.[@CR1],[@CR2],[@CR4],[@CR5],[@CR8]-[@CR10] Therefore, there is no strong evidence of a benefit for higher CO~2~ tensions compared with hypocapnia in perioperative patients.

To generate evidence to formulate guidelines on ETCO~2~ management during general anesthesia, we first need to understand current clinical practice. To our knowledge, it is unclear which target ETCO~2~ levels are currently used and whether these levels have changed over time. Therefore, this study aimed to investigate the practice pattern of ETCO~2~ levels over time in non-cardiothoracic surgery. We did not aim to study clinical outcomes. We hypothesized that the target ETCO~2~ level may have increased over time in response to the existing evidence described above. To further explore the practice pattern, we aimed to investigate four subgroups separately: patients with chronic obstructive pulmonary disease (COPD; subgroup 1); patients undergoing intracranial or carotid artery surgery (subgroup 2); and patients receiving laparoscopic surgery with (subgroup 3) or without (subgroup 4) robot assistance.

Methods {#Sec1}
=======

For this multicentre, retrospective, observational study, we used data from the Multicentre Perioperative Outcomes Group (MPOG) database. The MPOG registry, data entry process, and validation of data have been described in detail previously.[@CR18],[@CR19] In brief, MPOG is a consortium of 47 hospitals in North America and Europe, collecting perioperative data to facilitate outcomes research. Institutional Review Board (IRB) approval for MPOG was obtained from the University of Michigan Health System, MPOG's coordinating institution. Each participating institution has separate IRB approval to submit a limited set of perioperative data into the centralized database for future use, without any direct patient identifiers. Ethical approval for the current study was provided by the University Medical Center Utrecht, the leading institution for this project (May 2016, Number 16-282/C). The requirement for written informed consent was waived. No additional IRB approval was sought from other institutions. Additionally, the study protocol was reviewed *a priori* and approved by the MPOG Perioperative Clinical Research Committee (PCRC-0032, September 2016).

Patients {#Sec2}
--------

This study included all adult patients ≥ 18 yr who received general anesthesia between I January, 2008 and 9 January, 2016 at eight academic institutions affiliated with MPOG: University of Michigan Health System, Ann Arbor, Michigan; Oregon Health & Science University, Portland, Oregon; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Washington University School of Medicine, St. Louis, MO; University of Vermont Medical Center, Burlington, VT; Vanderbilt University, Nashville, TN; University Medical Center Utrecht, Utrecht, the Netherlands; and University of Pennsylvania Health System, Philadelphia, PA, USA. Only institutions submitting data for all variables mentioned below were selected for this study. For patients who received general anesthesia more than once within 30 days, only the first case was included. Exclusion criteria are presented in Fig. [1](#Fig1){ref-type="fig"}. These criteria were based on procedure type, a poor clinical condition prior to anesthesia, and suspected intraoperative hemodynamic instability to limit the risk of artifacts and invalid ETCO~2~ values. Vasopressor use per hour was used as a proxy for hemodynamic instability. Additionally, we excluded patients who received one-lung ventilation and ventilation by means of a laryngeal mask airway. To ensure sufficient time for data collection, cases with \< 40 min between incision and the end of the surgical procedure were excluded. Furthermore, patients with \< 20 valid machine-generated ETCO~2~ measurements were excluded.Fig. 1Flow chart. ASA = American Society of Anesthesiologist; CPT = current procedural terminology; ETCO~2~ = end-tidal carbon dioxide. LMA = laryngeal mask airway; MPOG = Multicenter Perioperative Outcomes Group. \*Blood transfusion \> two units was defined as: more than two units of packed cells or whole blood or more than 600 mL of cell saver blood during general anesthesia. †Patients were excluded when they met the inclusion criteria of more than one subgroup: e.g., chronic obstructive pulmonary disease (COPD) and laparoscopic surgery. ‡Only the first case within 30 days was included

*A priori*, we defined four subgroups of patients in whom the target ETCO~2~ level was considered to possibly differ from other patients: 1) patients with COPD, as their awake PaCO~2~ level may be increased and therefore a higher ETCO~2~ may be accepted[@CR20]; 2) patients undergoing intracranial and carotid artery surgery, as these interventions may compromise cerebral perfusion and therefore warrant a strict control of ETCO~2~;[@CR1],[@CR17] and patients receiving laparoscopic surgery with or without robot assistance (subgroups 3 and 4 respectively), as insufflation with carbon dioxide can increase the PaCO~2~, therefore higher ETCO~2~ levels may need to be tolerated.[@CR21]-[@CR23] We differentiated between laparoscopic surgery with and without robot assistance, since Trendelenburg positioning can further increase the PaCO~2~.[@CR22] All four subgroups were excluded from the primary analysis to avoid confounding the observed change in ETCO~2~ levels over time, especially because of an increasing utilization of laparoscopic over open procedures. Patients eligible for multiple groups were excluded from all analyses.

Outcome {#Sec3}
-------

The primary outcome was ETCO~2~ stratified into four groups (\< 28, \< 35, \< 45, and \> 45 mmHg) and the area-under-the-curve for each specific threshold was estimated with adjustment for the total measurement time, resulting in a time-weighted average area-under-the-curve (TWA-AUC) per threshold. Patients could be binned into multiple groups. Patients with at least one valid ETCO~2~ \< 28 mmHg were binned into the \< 28 mmHg group, but these data were also used for the \< 35 mmHg and \< 45 mmHg groups, respectively. If patients also had at least one valid ETCO~2~ value \> 45 mmHg, the corresponding TWA-AUC was binned into the \> 45 mmHg group.

To aid interpretation and clinical applicability, a median ETCO~2~ per case was obtained as a secondary outcome measure. *A priori*, a relative change of 10% in median ETCO~2~ over the entire study period was considered to be clinically relevant.

Data collection {#Sec4}
---------------

Data collection for intraoperative variables started ten minutes after surgical incision to ignore hyper- and hypocapnia that may follow mask ventilation and intubation during induction of anesthesia, and to allow the ETCO~2~ to reach a set level. Data collection ended ten minutes prior to the end of the surgical dressing to ignore increased values of ETCO~2~ that may be accepted to establish spontaneous ventilation. When the exact incision time was not registered, data collection started 20 min after anesthesia induction. Only valid ETCO~2~ values were used (see Table 1S, available as Electronic Supplementary Material for the artifact filter). Data were collected for ventilation parameters (tidal volume, respiratory rate, positive-end-expiratory pressure (PEEP), respiratory minute volume (RMV)) and mean arterial blood pressure (MAP) as potential confounders. Mean arterial pressure and ventilation parameters, including ETCO~2~, were measured continuously during general anesthesia by automated interfaces. An average of these results was recorded every minute in the anesthesia record-keeping system and stored in the centralized MPOG database.

Preoperative data on sex, height, body mass index (BMI), age, and American Society of Anesthesiologists (ASA) physical status were collected as covariates.[@CR24] For every case, we recorded the institution and determined the primary anesthesia provider, defined as the supervising anesthesiology faculty and primary anesthesia caregiver (either nurse anesthetist or resident) that provided anesthesia for at least 75% of the time.

Statistical analysis {#Sec5}
--------------------

Descriptive statistics were computed using frequencies and percentages for categorical variables and medians with interquartile ranges \[IQR\] for continuous data after checking continuous variables for normality using the Kolmogorov-Smirnov test.

Differences in baseline characteristics, ventilation parameters, and mean MAP between the primary cohort and the subgroups and between the beginning and end of the study were analyzed using a Kruskal-Wallis test.

For all four thresholds, the TWA-AUC of each patient was computed from minute-level ETCO~2~ values using a fitted cubic spline curve (see Figure available as Electronic Supplementary Material showing the method to calculate the area-under-the-curve). For every case, a median was calculated for tidal volume, respiratory rate, PEEP, and RMV. We determined the mean MAP for every case, as a summary measure for the overall blood pressure.

Both the TWA-AUC and median ETCO~2~ were plotted over time and values were compared between years using a Kruskal-Wallis test. Medians and IQR were reported.

Prior to the start of this study, we surveyed all participating centres to gain insight into target ETCO~2~ levels and factors that might have influenced these levels during the study period. The full survey can be found in the Supplemental Material. When abrupt changes in ETCO~2~ were reported by at least half of all institutions, an interrupted time series (ITS) analysis was considered.

To examine variation in ETCO~2~, patient characteristics were compared between patients with a median ETCO~2~ \< 5^th^ percentile, between the 5^th^ and 95^th^ percentile, and \> 95^th^ percentile using a Kruskal-Wallis test. To examine variation between and within each institution, six mixed-effect multivariable logistic regression models were built. A positive TWA-AUC ETCO~2~ \> 45 mmHg (meaning that at least one ETCO~2~ value per case was \> 45 mmHg) was used as a binary outcome measure in all models. Before any regression models were constructed, all variables under consideration for model inclusion were checked for collinearity using the condition index. If the condition index was \> 30, a Pearson's correlation matrix was developed. Those variables deemed to be collinear (defined as a correlation of ≥ 0.70) were either combined into a single variable or removed. All non-collinear variables were entered into the models. The included fixed effects were selected based upon clinical relevance: age (binned per decade, reference group 18--30), sex, BMI (binned into \< 18.5, 18.5--24.9 (reference group), 25.0--29.9, 30.0--34.9, 35.0--39.9, ≥ 40.0 kg·m^−2^), ASA class (I or II *vs* III, IV, V), median tidal volume (binned by ideal body weight into \< 6, 6--8 (reference group), 8--10, \> 10 mL·kg^−1^), median respiratory rate (binned into \< 12, 12--16 (reference group), 16--20, \> 20 min^−1^), median PEEP (binary, \< 5 or ≥ 5 cmH~2~O), mean MAP (\< 65, 65--80 (reference group), \> 80 mmHg), and year of the procedure. All six mixed-effects models contained the same fixed effects with differing random effects between the models. The first model used institution as a random effect to examine the variation between institutions; the second model used primary anesthesia caregiver, and the third used supervising anesthesiology faculty as random effects to examine how much of the variation could be explained by inter-provider variability. The fourth model used supervising anesthesiology faculty nested within institution as a random effect and the fifth model used primary anesthesia caregiver nested within institution to further explore variation due to preferences of a provider within a specific institution. The final model was built with primary anesthesia caregiver nested within supervising anesthesiology faculty, which was again nested within institution, as the random effect. This model was built to explore how much of the variation could be explained by a particular anesthesia care team in a specific institution. Measures of effect size for random effects were reported as intraclass correlation coefficients (ICC) and median odds ratios (MOR) with corresponding 95% confidence intervals (CI).[@CR25]

All analyses were conducted for the general cohort and the subgroups separately. A *P* value of 0.05 was considered statistically significant for all analyses.

The analyses were conducted using SAS v. 9.4 (SAS Institute, Cary, NC, USA) and Stata v. 13.1 (StataCorp LLC; College Station, TX, USA). The study was conducted in adherence to the STROBE statement for observational research.[@CR26]

Results {#Sec6}
=======

One million, seven hundred and ninety-four thousand, seven hundred and seventy-three patients met the initial inclusion criteria of general anesthesia and age. After application of all *a priori* defined exclusion criteria and after exclusion of invalid observations, 317,445 patients were eligible. We included 245,725 patients in our primary analysis and 71,720 patients in different subgroups (Fig. [1](#Fig1){ref-type="fig"}). Patient characteristics for the primary cohort and the subgroups are described in Table [1](#Tab1){ref-type="table"}. Additionally, differences in patient characteristics between 2008 and 2016 are shown in Table [2](#Tab2){ref-type="table"}. Over time, patients were slightly older, had a higher BMI, and had a higher ASA class. RMV slightly decreased over time, whereas the mean MAP increased over time. The duration of both the procedure and general anesthesia decreased over time.Table 1Baseline characteristics for the general cohort and the subgroupsGeneral cohort\
(*n* = 245,725)Intracranial and carotid artery surgery\
(*n* = 12,527)Laparoscopic\
surgery\
(*n* = 44,507)Robotic laparoscopic surgery\
(*n* = 12,977)COPD\
(*n* = 1709)Age (yr)\*51 \[38--63\]53 \[39--64\]49 \[36--60\]60 \[52--66\]65 \[55--73\]Sex (female)†124782 (50.8)6442 (51.4)28661 (64.4)3364 (25.9)810 (47.40)ASA physical status†\
I\
II\
III\
IV\
V27738 (11.3)\
125488 (51.1)\
84835 (34.5)\
7603 (3.1)\
61 (0.02)735 (5.9)\
4736 (37.8)\
6447 (51.5)\
598 (4.8)\
11 (0.1)4494 (10.1)\
23039 (51.8)\
16351 (36.7)\
622 (1.4)\
1 (0.0)513 (4.0)\
7705 (59.4)\
4667 (36.0)\
92 (0.7)\
0 (0.0)0 (0.0)\
341 (20.0)\
1173 (68.6)\
192 (11.2)\
3 (0.2)Height (cm)\*170 \[163--178\]170 \[163--178\]168 \[162--175\]175 \[168--182\]170 \[160--178\]BMI (kg·m^−2^)\*27.8 \[24.1--32.7\]27.3 \[23.8--31.7\]29.8 \[25.1--37.3\]28.7 \[25.6--32.6\]27.2 \[23.4--32.6\]Median RMV (mL·min^−1^)\*5571 \[4660--6590\]6012 \[4960--7238\]6288\[5391--7330\]6720 \[5860--7692\]5560 \[4728--6504\]Median respiratory rate\*10 \[9--12\]12 \[10--13\]12 \[10--14\]12 \[10--14\]10 \[9--12\]Median ETCO~2~ (mmHg)\*34.0 \[32.0--36.0\]32.0 \[29.0--34.0\]36.0 \[34.0--38.0\]36.0 \[33.0--38.0\]34.0 \[32.0--37.0\]Mean MAP (mmHg)\*78 \[72--85\]81 \[75--87\]82 \[76--89\]83 \[77--89\]80 \[74--86\]Duration of general anesthesia (min)\*170 \[129--232\]233 \[173--325\]167 \[126--225\]251 \[213--301\]197 \[150--265\]Duration of surgery (min)\*103 \[70--155\]133 \[84--211\]106 \[72--153\]179 \[145--226\]122 \[83--186\]\*Median \[interquartile range\]; †Count and %ASA = American Society of Anesthesiologist; BMI = body mass index; COPD = chronic obstructive pulmonary disease; ETCO~2~ = end-tidal carbon dioxide; MAP = mean arterial pressure; RMV = respiratory minute ventilationTable 2Baseline characteristics and ETCO~2~ levels for 2008 and 2016Case year 2008\
(*n* = 23434)Case year 2016\
(*n* = 18797)*P* Value[General cohort]{.ul}Age (yr)†50 \[38--62\]52 \[37--64\]\< 0.001\*Sex (female)‡11922 (50.9)9511 (50.6)\< 0.001\*ASA physical status‡\< 0.001\*I3148 (13.4)1965 (10.5)II12477 (53.2)9209 (49.0)III7130 (30.4)6986 (37.2)IV672 (2.9)632 (3.4)V7 (0.03)5 (0.03)Height (cm)†170 \[163--178\]170 \[163--178\]0.14BMI (kg·m^−2^)†27.4 \[23.9--32.1\]28.09 \[24.2--33.1\]\< 0.001Median RMV (mL·min^−1^)†5665 \[4744--6708\]5480 \[4572--6468\]\< 0.001Mean MAP†77 \[71--84\]80 \[73--86\]\< 0.001Duration of general anesthesia (min)†178 \[134--241\]167 \[127--224\]\< 0.001Duration of surgery (min)†106 \[72--160\]102 \[69--153\]\< 0.001\*TWA-AUC ETCO~2~ \< 28 mmHg0.0 \[0.0--1.0\]0.0 \[0.0--0.0\]\< 0.001\*TWA-AUC ETCO~2~ \< 35 mmHg169.0 \[57.8--351.8\]45.4 \[2.0--161.9\]\< 0.001\*TWA-AUC ETCO~2~ \< 45 mmHg986.9 \[573.5--1621.8\]713.2 \[385.0--1218.1\]\< 0.001\*TWA-AUC ETCO~2~ \> 45 mmHg0.0 \[0.0--0.0\]0.0 \[0.0--2.73\]\< 0.001\*Median ETCO~2~ (mmHg)33.0 \[31.0--35.0\]35.0 \[33.0--38.0\]\< 0.001\*[Intracranial and carotid artery surgery]{.ul}†TWA-AUC ETCO~2~ \< 28 mmHg0.0 \[0.0--35.0\]0.0 \[0.0--17.0\]0.03\*TWA-AUC ETCO~2~ \< 35 mmHg376.5 \[145.0--812.5\]181.0 \[28.4--658.3\]\< 0.001\*TWA-AUC ETCO~2~ \< 45 mmHg1581.3 \[841.5--2680.7\]1238.9 \[622.1--2292.3\]\< 0.001\*TWA-AUC ETCO~2~ \> 45 mmHg0.0 \[0.0--0.0\]0.0 \[0.0--0.0\]0.001\*Median ETCO~2~ (mmHg)31.6 \[29.0--33.0\]33.0 \[30.0--36.0\]\< 0.001\*[Laparoscopic surgery]{.ul}†TWA-AUC ETCO~2~ \< 28 mmHg0.0 \[0.0--0.0\]0.0 \[0.0--0.0\]\< 0.001\*TWA-AUC ETCO~2~ \< 35 mmHg76.3 \[19.0--193.3\]17.3 \[0.34--77.1\]\< 0.001\*TWA-AUC ETCO~2~ \< 45 mmHg856.9 \[489.7--1408.2\]574.0 \[327.5--990.2\]\< 0.001\*TWA-AUC ETCO~2~ \> 45 mmHg0.0 \[0.0 to1.0\]0.0 \[0.0--3.58\]\< 0.001\*Median ETCO~2~ (mmHg)35.0 \[33.0--37.0\]37.0 \[35.0--40.0\]\< 0.001\*[Robotic laparoscopic surgery]{.ul}†TWA-AUC ETCO~2~ \< 28 mmHg0.0 \[0.0--0.0\]0.0 \[0.0--0.0\]0.03\*TWA-AUC ETCO~2~ \< 35 mmHg140.2 \[31.9--327.9\]58.5 \[7.0--187.0\]\< 0.001\*TWA-AUC ETCO~2~ \< 45 mmHg1538.9 \[1099.0--2028.5\]1306.3 \[849.1--1884.4\]\< 0.001\*TWA-AUC ETCO~2~ \> 45 mmHg0.0 \[0.0--4.0\]0.0 \[0.0--19.0\]\< 0.001\*Median ETCO~2~ (mmHg)35.0 \[33.0--37.7\]37.0 \[35.0--39.0\]\< 0.001\*COPD†TWA-AUC ETCO~2~ \< 28 mmHg0.0 \[0.0--2.0\]0.0 \[0.0--0.0\]0.06TWA-AUC ETCO~2~ \< 35 mmHg162.4 \[41.3--394.0\]22.8 \[1.5--164.5\]\< 0.001\*TWA-AUC ETCO~2~ \< 45 mmHg1151.0 \[658.0--1989.1\]728.9 \[390.4--1264.8\]\< 0.001\*TWA-AUC ETCO~2~ \> 45 mmHg0.0 \[0.0--0.24\]0.0 \[0.0--21.6\]\< 0.001\*Median ETCO~2~ (mmHg)34.0 \[32.0--36.0\]36.0 \[ 34.0--39.0\]\< 0.001\***\***Statistically significant at a level of significance of *P* \< 0.05 †Median \[interquartile range\]. ‡Count and %ASA = American Society of Anesthesiologist; BMI = body mass index; COPD = chronic obstructive pulmonary disease. ETCO~2~ = end-tidal carbon dioxide; MAP = mean arterial pressure; RMV = respiratory minute ventilation; TWA-AUC = time-weighted average area-under-the-curve

Change in ETCO~2~ over time {#Sec7}
---------------------------

The mean TWA-AUC per quarter of a year was plotted for all four ETCO~2~ thresholds (Fig. [2](#Fig2){ref-type="fig"}, data for the general cohort) and showed that more time was spent closer to or above the threshold of 45 mmHg. There was a statistically significant decrease in TWA-AUC from 2008 to 2016 for an ETCO~2~ \< 28 mmHg, \< 35 mmHg, and \< 45 mmHg, whereas a TWA-AUC ETCO~2~ \> 45 mmHg significantly increased over time (Table [2](#Tab2){ref-type="table"}). The median \[IQR\] ETCO~2~ was plotted over time (Fig. [3](#Fig3){ref-type="fig"}a) and showed a minimal increase from 33 \[31.0--35.0\] mmHg in 2008 to 35 \[33.0--38.0\] mmHg (*P* \< 0.001) in 2016.Fig. 2Trend in TWA-AUC ETCO~2~ for four different thresholds. The trend over time in mean time-weighted average area-under-the-curve (TWA-AUC) per quarter for an end-tidal carbon dioxide levels (ETCO~2~) of \< 28 mmHg, \< 35 mmHg, \< 45 mmHg, and \> 45 mmHg. The TWA-AUC decreased over time for an ETCO~2~ threshold of \< 28, \< 35, and \< 45 mmHg, whereas the TWA-AUC ETCO~2~ \> 45 mmHg increased over timeFig. 3Trend in median ETCO~2~ over time. The boxplots show an increase in median end-tidal carbon dioxide (ETCO~2~) values between 2008 and 2016 for the general cohort (A) and the subgroups (B--E). The triangle represents the mean, the whiskers represent the spread between the 10^th^ and 90^th^ percentile. The median ETCO~2~ was lower for patients presenting for intracranial and carotid artery surgery (B) compared with the general cohort. The median ETCO~2~ was higher for patients in the (robotic) laparoscopic cohort (C, D) and for patients with chronic obstructive pulmonary disease (COPD) (E) compared with the general cohort (A)

Similar trends were obtained for the subgroups over time (Fig. [3](#Fig3){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). Nevertheless, the ETCO~2~ was lower for patients presenting for intracranial and carotid artery surgery and higher for patients in the (robotic) laparoscopic cohort and for patients with COPD (see also Table 2S, available as Electronic Supplementary Material, showing the median ETCO~2~ and TWA-AUC per threshold for the general cohort and all subgroups).

In the survey, two out of eight (25%) institutions reported a decrease in RMV between 2008 and 2016, and one institution (12.5%) reported an increase in RMV. Three institutions (37.5%) reported an increase in target ETCO~2~ level varying between 2 and 5 mmHg. Since a minority of institutions reported a change in time, we refrained from conducting ITS analysis. Results from the survey are summarized in Table 3S in the Electronic Supplementary Material.

Variation in ETCO~2~ {#Sec8}
--------------------

The median ETCO~2~ plots showed a large spread between the 10^th^ and 90^th^ percentile (Fig. [3](#Fig3){ref-type="fig"}). Characteristics of patients with a median ETCO~2~ \< 5^th^ percentile (\< 29 mmHg), between the 5^th^ and 95^th^ percentile (29--41 mmHg), and **\>** 95^th^ percentile (41 mmHg) were compared (see Table 4S available as Electronic Supplementary Material showing the baseline characteristics by percentile). Patients with a higher median ETCO~2~ were, on average, younger, had a higher BMI, a lower ASA class, and were more often male. The median RMV was lower for patients with a higher median ETCO~2~. The duration of both general anesthesia and surgery was longest for patients with an intermediate ETCO~2~ (between 29 and 41 mmHg).

After adjusting for patient characteristics, ventilation parameters, and mean MAP, an ICC of 0.18 (95% CI, 0.07 to 0.37) was found for a model using institution as a random effect, 0.17 (95% CI, 0.16 to 0.19) for a model with primary anesthesia caregiver as a random effect, and 0.12 (95% CI, 0.11 to 0.14) for a model with supervising anesthesiology faculty as a random effect (Table [3](#Tab3){ref-type="table"}). An ICC of 0.36 (95% CI, 0.18 to 0.58) was found for a model with primary anesthesia caregiver nested within a specific supervising anesthesiology faculty, nested within a specific institution, as a random effect. This corresponded with a MOR of 1.98 (95% CI, 1.90 to 2.07). In this, the MOR can be interpreted as the median increase in the odds of having at least one ETCO~2~ value per case **\>** 45 mmHg, when an individual moves from a one cluster to another. The subgroup consisting of patients with COPD was too small to conduct random-effect multivariable logistic regression models.Table 3Institutional and provider variationRandom effect per model\*General cohort\
*n* = 245,725Intracranial and carotid artery surgery\
*n* = 12,527Laparoscopic surgery\
*n* = 44,507Robotic laparoscopic surgery\
*n* = 12,977InstitutionICC (95% CI)\
MOR (95% CI)0.18 (0.07--0.37)\
1.96 (1.28--6.32)0.14 (0.05--0.33)\
1.66 (1.19--4.55)0.11 (0.04--0.26)\
1.44 (1.13--2.95)0.22 (0.09--0.44)\
2.36 (1.34--12.15)Supervising anesthesiology facultyICC (95% CI)\
MOR (95% CI)0.12 (0.11--0.14)\
1.56 (1.45--1.69)0.18 (0.12--0.25)\
1.96 (1.54--2.84)0.05 (0.04--008)\
1.20 (1.13--1.29)0.19 (0.15--0.24)\
2.10 (1.75--2.69)Primary anesthesia caregiverICC (95% CI)\
MOR (95% CI)0.17 (0.16--0.19)\
1.91 (1.79--2.06)0.15 (0.10--0.21)\
1.79 (1.44--2.24)0.14 (0.12--0.16)\
1.68 (1.55--1.84)0.30 (0.26--0.35)\
3.86 (2.91--5.51)Supervising anesthesiology faculty nested within institutionICC (95% CI)\
MOR (95% CI)0.23 (0.09--0.49)\
1.08 (1.06--1.10)0.22 (0.10--0.40)\
1.42 (1.23--1.83)0.12 (0.03--0.37)\
1.12 (1.03--1.42)0.18 (0.05--0.46)\
1.05 (1.02--1.13)Primary anesthesia caregiver nested within institutionICC (95% CI)\
MOR (95% CI)*Did not converge*0.23 (0.11--4.23)\
1.34 (1.18--1.68)0.17 (0.08--.31)\
1.26 (1.20--1.34)0.31 (0.14--0.55)\
1.39 (1.26--1.60)Primary anesthesia caregiver nested within supervising anesthesiology faculty, nested within institutionICC (95% CI)\
MOR (95% CI)0.36 (0.18--0.58)\
1.98 (1.90--2.07)0.26 (0.12--0.48)\
1.21 (1.01--31.25)0.27 (0.16--0.42)\
1.29 (1.16--1.49)0.37 (0.19--0.59)\
2.06 (1.58--3.12)\*Dependent variable: positive TWA-AUC ETCO~2~ \> 45 mmHg (yes/no). Fixed effects: age (binned per decade), body mass index (binned into \< 18.5, 18.5--24.9, 25.0--29.9, 30.0--34.9, 35.0--39.9, ≥ 40.0 kg·m^−2^), sex, ASA class (I or II *vs* III, IV, or V), positive end-expiratory pressure (binary, \< 5 or ≥ 5mmHg), tidal volume (binned by ideal body weight into \< 6, 6--8, 8--10, \>10 mL·kg^−1^), median respiratory rate (binned into \< 12, 12--16, 16--20, \> 20·min^−1^), mean of the mean arterial blood pressure (binned \< 65, 65--80, \> 80 mmHg) and year of procedure. Random effects differed per model and included institution, primary anesthesia caregiver, and/or attending anesthesiologistThe subgroup of patients with a history of chronic obstructive pulmonary disease was too small to conduct random-effect multivariable logistic regression analysesCI = confidence interval; ICC = intraclass correlation coefficient; MOR = median odds ratio

Discussion {#Sec9}
==========

Between 2008 and 2016, median ETCO~2~ levels increased minimally, but this change did not meet the *a priori*-defined clinically relevant threshold of 10%. A large variation in target ETCO~2~ levels was observed between institutions and between providers for the general cohort and all subgroups. Interestingly, only a minority of this variation could be attributed to the institution and anesthesia provider, while controlling for patient characteristics. The amount of variability that could be attributed to institution and primary anesthesia caregiver was overall slightly larger than the amount that could be attributed to the supervising anesthesiology faculty, except for intracranial and carotid artery surgery, where the preference of the supervising anesthesiology faculty seemed to be more important than the effect of institution and primary anesthesia caregiver.

Practice variation in targeted ETCO~2~ levels has not been studied previously. Large practice variation across regions, institutions, and physicians is reported throughout the medical field.[@CR27] Previously, a variation of 18% in tidal volume was shown to be attributable to institutional variability.[@CR24] The same amount of variation could be attributed to institutional variability in our study.

The large variation in ETCO~2~ found in this study may have several implications. It raises the question whether anesthesia providers care for any ETCO~2~ target at all, or at least it could be theorized that ETCO~2~ levels are not as important as maintaining, for example, adequate blood pressure levels or oxygen saturation. Likely, there is insufficient knowledge about the effects of ETCO~2~ levels to guide anesthesia providers in targeting specific ETCO~2~ levels. We believe further exploration of the effect of intraoperative ETCO~2~ levels on postoperative outcome is required to determine what ETCO~2~ level should be aimed for to improve patient outcome. This research group has initiated two new projects to study the association between intraoperative ETCO~2~ levels and postoperative pulmonary complications, and the association between intraoperative ETCO~2~ levels and neurologic outcome in the neurosurgical population.

As all retrospective analyses, this study has limitations. First, we did not differentiate between spontaneous and controlled ventilation, but we only included cases with endotracheal tubes placed. By excluding cases managed with laryngeal mask airways, the likelihood of spontaneous breathing patterns was reduced significantly. It could be argued that some of the residual spontaneous breathing might lead to a higher ETCO~2~ level and that this may explain the observed variation. Nevertheless, we would expect that an inacceptable ETCO~2~ level (either hyper- or hypocapnia) would be corrected by the anesthesia provider. Therefore, since the aim of this study was to investigate which levels are being accepted, we did not differentiate between these ventilation methods. Second, the use of certain ventilator modes might be associated with the practice pattern in ETCO~2~ levels, e.g., a volume-controlled ventilation mode with a specific default setting, but this was not taken into account in this study. As became apparent from the survey, the majority of institutions used a strictly controlled default ventilation mode. Third, a TWA-AUC is not easily applicable in daily practice. Nevertheless, our primary aim was to investigate the practice pattern over time for further research purposes and we believe that a median ETCO~2~ per case would not suffice to summarize a case adequately. Four ranges of ETCO~2~ and thus four different TWA-AUC values per case allowed us better to summarize a very long case compared with one overall value. The median ETCO~2~ was added as a secondary outcome measure to aid interpretation and clinical applicability. Fourth, the intraoperative time-frame used for data collection was chosen based upon expert consensus. We aimed to collect data during a relatively stable phase of general anesthesia. We checked timeframes in randomly selected cases and found a good correspondence with the maintenance phase of anesthesia. Finally, although we adjusted the results for a large set of potential confounders, residual confounding might be present because of the retrospective nature of this study.

Conclusion {#Sec10}
==========

There was no clinically relevant change in intraoperative ETCO~2~ levels between 2008 and 2016. Nevertheless, there was a very large practice variation, even within institutions and providers that could not be fully explained by differences in patient or procedure characteristics. Although existing literature suggests that ETCO~2~ levels of 40 mmHg or higher might be associated with better outcomes in mechanically-ventilated patients,[@CR4],[@CR5],[@CR9],[@CR17],[@CR28] this is not reflected in current clinical anesthesia practice. Clinical outcomes were not assessed in this study and should be the focus of future research to formulate clear guidelines.
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